However, early diagnosis is difficult due to a lack of obvious symptoms, and as such, it is usually identified in screening programmes aimed at older men.

Finding ways to identify pre-cancer cells and early disease has become a key research area.

There is also a focus towards early detection programmes, and this has increasingly become part of educational initiatives.

The most commonly used treatments include radical prostatectomy, radiotherapy and hormonal therapy.

More recently, medical attitudes have switched towards the use of combination approaches as a way of improving outcomes and minimising toxicities by using lower doses. In light of which, there is scope for the introduction of non-hormonal treatments for use in combinations.

Despite an overwhelming number of treatments, prostate cancer remains a therapeutic opportunity as most patients develop hormone refractory prostate cancer (HRPC).

Identifying a treatment that can prevent or manage HRPC remains an unachieved ‘milestone’ in prostate cancer treatment.

An agent that is effective in prostate cancer is also likely to be beneficial in other cancers and in endometriosis – URODOC understands this ‘up-and-coming’ approach, and could be a valuable partner in developing a more global strategy.